More men at risk for prostate cancer as a result of less regular screening

Share this content:

the ONA take:

A recent research study examined the potential benefits and potential downsides to the US Preventive Services Task Force (USPSTF) recommendation against regular prostate-specific antigen (PSA) screening for prostate cancer.

Researchers, led by Daniel A. Barocas, MD, MPH, of the Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, examined the number and distribution of new prostate cancer diagnoses in the United States.

Incident cancers diagnosed from January 2010 through December 2012 were included. The number of new prostate cancer cases diagnosed before and after the USPSTF recommendation were compared against a similar record of colon cancer findings.

The investigators found a drop in the number of prostate cancer diagnoses, a greater than 12% decline, following the USPSTF's PSA screening recommendation.

Prostate cancer diagnoses at all risk levels fell, though new diagnoses of nonlocalized disease did not change. Monthly colon cancer diagnoses remained steady before and after the USPSTF recommendation.

One year after the USPSTF recommendation, diagnoses of new low risk cancers dropped by nearly 38%, which does address the USPSTF intent to reduce overdiagnosis, but the researchers have concerns that the reduction in high- and immediate-risk disease diagnoses could lower chances for early detection and treatment.

pThe team feels that additional research into screening models to maximize early detection for higher risk cancers while keeping overdiagnosis and overtreatment numbers low would be beneficial.

Data from this study were published in The Journal of Urology

How many men actually speak to their doctor about prostate cancer symptoms?
A recent study examined the potential benefits and potential downsides to the USPSTF recommendation against regular PSA screening.
The U.S. Preventive Services Task Force (USPSTF) recommendation against regular prostate specific antigen (PSA) screening for prostate cancer is controversial. While it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology.
READ FULL ARTICLE From Medical Express
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs